<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">STD</journal-id>
<journal-id journal-id-type="hwp">spstd</journal-id>
<journal-title>International Journal of STD &amp; AIDS</journal-title>
<issn pub-type="ppub">0956-4624</issn>
<issn pub-type="epub">1758-1052</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0956462412472792</article-id>
<article-id pub-id-type="publisher-id">10.1177_0956462412472792</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Audit report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An audit of pharyngeal gonorrhoea treatment in a public sexual health clinic in Adelaide, South Australia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hustig</surname><given-names>A</given-names></name><degrees>BMBS</degrees>
<xref ref-type="aff" rid="aff1-0956462412472792">*</xref>
<xref ref-type="corresp" rid="corresp1-0956462412472792"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bell</surname><given-names>C</given-names></name><degrees>FCAS FAChSHM</degrees>
<xref ref-type="aff" rid="aff2-0956462412472792">†</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Waddell</surname><given-names>R</given-names></name><degrees>FAChSHM MBBS</degrees>
<xref ref-type="aff" rid="aff2-0956462412472792">†</xref>
</contrib>
</contrib-group>
<aff id="aff1-0956462412472792"><label>*</label>School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia</aff>
<aff id="aff2-0956462412472792"><label>†</label>Clinic 275, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia</aff>
<author-notes>
<corresp id="corresp1-0956462412472792"><bold>Correspondence to:</bold> Alistair Hustig Email: <email>alistair.hustig@internode.on.net</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>24</volume>
<issue>5</issue>
<fpage>399</fpage>
<lpage>400</lpage>
<history>
<date date-type="accepted">
<day>22</day>
<month>11</month>
<year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract><title>Summary</title>
<p>In recent times there have been changes to guidelines regarding the management of gonorrhoea, from both the Centers for Disease Control and Prevention in 2010 and the British Association for Sexual Health and HIV (BASHH) in 2011. Coinciding with their release we conducted a clinical audit of our treatment protocol for gonorrhoea. In 2010, local data on the minimum inhibitory concentrations for <italic>Neisseria gonorrhoeae</italic> indicated an increase in local isolates that were less sensitive to ceftriaxone (11.6% c.f. 5.3% in 2009). We have a long history of using 250 mg of ceftriaxone to treat all standard sites of gonorrhoea infection followed with tests of cure in all cases. In a retrospective clinical audit of an 11-year period from 2000 up to and including 2010 we identified six test-of-cure failures over 11 years after treating a total of 215 patients with pharyngeal gonorrhoea.</p>
</abstract>
<kwd-group>
<kwd>Neisseria gonorrhoeae</kwd>
<kwd>gonorrhoea</kwd>
<kwd>sexually transmitted infection</kwd>
<kwd>treatment</kwd>
<kwd>pharyngeal gonorrhoea</kwd>
<kwd>antibiotics</kwd>
<kwd>ceftriaxone</kwd>
<kwd>resistance</kwd>
<kwd>treatment failure</kwd>
<kwd>test of cure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro"><title>INTRODUCTION</title>
<p>Pharyngeal gonorrhoea is important as is it is asymptomatic in over 90% of cases but still provides a potential source of transmission from oropharynx to urogenital surfaces.<sup><xref ref-type="bibr" rid="bibr1-0956462412472792">1</xref><xref ref-type="bibr" rid="bibr2-0956462412472792"/><xref ref-type="bibr" rid="bibr3-0956462412472792"/>–<xref ref-type="bibr" rid="bibr4-0956462412472792">4</xref></sup> Furthermore it is more difficult to treat than other sites of infection<sup><xref ref-type="bibr" rid="bibr5-0956462412472792">5</xref></sup> as it is thought that pharyngeal concentrations of antimicrobials are not as high as genital and rectal mucosal surfaces.<sup><xref ref-type="bibr" rid="bibr6-0956462412472792">6</xref></sup> Already <italic>Neisseria gonorrhoeae</italic> has proven resistance to antimicrobial agents including beta-lactams, tetracyclines, fluoroquinolones and cefixime.<sup><xref ref-type="bibr" rid="bibr7-0956462412472792">7</xref></sup> Due to the recent identification of two pharyngeal ceftriaxone failures in Australia,<sup><xref ref-type="bibr" rid="bibr8-0956462412472792">8</xref></sup> and the <italic>H041</italic> strain, the threat is clear that the same is occurring with ceftriaxone. This strain, identified from a pharyngeal swab of an asymptomatic female commercial sex worker in Japan, was found to have a very high minimum inhibitory concentration (MIC) of 2 μg/mL.<sup><xref ref-type="bibr" rid="bibr9-0956462412472792">9</xref></sup> As this increases the duration of free-ceftriaxone above the MIC decreases,<sup><xref ref-type="bibr" rid="bibr9-0956462412472792">9</xref></sup> which is of even more importance when targeting difficult-to-penetrate tissue such as the pharynx.</p>
<p>Clinic 275 is an open access state-funded sexual health service in South Australia. It operates on a walk-in basis with no appointments, does not charge for services or treatments and requests no proof of identity. In 2010 the clinic recorded 8595 episodes of care resulting in 17,337 attendances for 6828 individuals.<sup><xref ref-type="bibr" rid="bibr10-0956462412472792">10</xref></sup></p>
</sec>
<sec id="sec2" sec-type="methods"><title>METHOD</title>
<p>We used our clinic database<sup><xref ref-type="bibr" rid="bibr11-0956462412472792">11</xref></sup> to identify all patients attending Clinic 275 who were diagnosed and treated for pharyngeal gonorrhoea from 2000 up to and including 2010. We developed and used a standardized audit tool to review case-notes and collect data. The data were entered into an Excel spreadsheet for analysis.</p>
</sec>
<sec id="sec3" sec-type="results"><title>RESULTS</title>
<p>Our audit identified six test-of-cure (TOC) failures over 11 years treating a total of 215 patients with pharyngeal gonorrhoea. The first of these occurred in 2006, with two in 2008 and three in 2010. Throughout this time our treatment practice had not changed. We continued to discourage all sexual encounters between testing, treatment and TOC results. Intramuscular ceftriaxone 250 mg was given to 204 patients (95%) in line with our protocol for treating gonorrhoea at that time; 149 patients (69.6%) received ceftriaxone alone and 55 (25.7%) were given additional azithromycin 1000 mg orally for concurrent chlamydial infection. Following treatment, 174 (80.9%) patients had a TOC. Throughout the 11 years this involved bacterial culture for <italic>Neisseria</italic>.</p>
<p>Six patients failed their TOC but all isolates were fully sensitive to cephalosporins (MIC &lt; 0.03 μg/mL). All six were men, with four having sex with men and two with both men and women. Five of the six failed TOC cases received only ceftriaxone (of 149 patients) and the other received ceftriaxone and additional azithromycin (of 55 patients) for concurrent urethral and rectal chlamydial infection. Following the TOC failure they were all treated with a further dose of 250 mg of ceftriaxone alone. On average patients re-attended for TOC at 9.3 days (range 5–21 days) after initial treatment for gonorrhoea and were re-treated at an average of 11 days (range 5–30 days) after their TOC was collected. At each presentation a repeat sexual history was taken and they all reported having abstained from sex during this period.</p>
</sec>
<sec id="sec4" sec-type="conclusions"><title>CONCLUSION</title>
<p>In order to minimize the spread of infection it is essential that pharyngeal gonorrhoea, especially due to its asymptomatic nature, be cured on first treatment. In light of our findings, the increased frequency of less sensitive ceftriaxone strains noted locally, and along with changes to CDC and BASHH guidelines, Clinic 275 has changed its guidelines. We now treat uncomplicated gonococcal infections with ceftriaxone 500 mg intramuscularly and azithromycin 1000 mg orally with recall for TOC in all. We hope this helps to arrest the development of antibiotic resistance in this exceedingly adaptable bacterium.</p>
</sec>
</body>
<back>
<ref-list><title>References</title>
<ref id="bibr1-0956462412472792"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bignell</surname><given-names>C</given-names></name><name><surname>FitzGerald</surname><given-names>M</given-names></name></person-group>. <article-title>UK national guideline for the management of gonorrhoea in adults, 2011</article-title>. <source>Int J STD AIDS</source> <year>2011</year>;<volume>22</volume>:<fpage>541</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr2-0956462412472792"><label>2</label><citation citation-type="journal"><collab>Centers for Disease Control and Prevention</collab>. <article-title>Sexually transmitted diseases treatment guidelines, 2010</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> <year>2010</year>;<volume>59</volume>(<supplement>No. RR-12</supplement>):<fpage>49</fpage>–<lpage>52</lpage>.</citation></ref>
<ref id="bibr3-0956462412472792"><label>3</label><citation citation-type="journal"><collab>Australian Gonococcal Surveillance Program</collab>, <comment>Annual Report 2010. Communicable Diseases Intelligence</comment>. <year>2011</year>;<volume>35</volume>(<issue>3</issue>):<fpage>229</fpage>–<lpage>36</lpage></citation></ref>
<ref id="bibr4-0956462412472792"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>KT</given-names></name><name><surname>Stephens</surname><given-names>SC</given-names></name><name><surname>Barry</surname><given-names>PM</given-names></name><etal/></person-group> <article-title><italic>Chlamydia trachomatis</italic> and <italic>Neisseria gonorrhoeae</italic> transmission from the oropharynx to the urethra among men who have sex with men</article-title>. <source>Clin Infect Dis</source> <year>2009</year>;<volume>49</volume>:<fpage>1793</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr5-0956462412472792"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>LM</given-names></name><name><surname>Moran</surname><given-names>JS</given-names></name><name><surname>Workowski</surname><given-names>KA</given-names></name></person-group>. <article-title>Update on the management of gonorrhea in adults in the United States</article-title>. <source>Clin Infect Dis</source> <year>2007</year>;<volume>44</volume>(<supplement>Suppl. 3</supplement>):<fpage>S84</fpage>–<lpage>101</lpage></citation></ref>
<ref id="bibr6-0956462412472792"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>JS</given-names></name></person-group>. <article-title>Treating uncomplicated <italic>Neisseria gonorrhoeae</italic> infections: is the anatomic site of infection important?</article-title> <source>Sex Transm Dis</source> <year>1995</year>;<volume>22</volume>:<fpage>39</fpage>–<lpage>47</lpage></citation></ref>
<ref id="bibr7-0956462412472792"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohnishi</surname><given-names>M</given-names></name><name><surname>Golparian</surname><given-names>D</given-names></name><name><surname>Shimuta</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Is <italic>Neisseria gonorrhoeae</italic> initiating a future era of untreatable gonorrhea?</article-title> <source>Antimicrob Agents Chemother</source> <year>2011</year>;<volume>55</volume>:<fpage>3538</fpage>–<lpage>45</lpage></citation></ref>
<ref id="bibr8-0956462412472792"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tapsall</surname><given-names>J</given-names></name><name><surname>Read</surname><given-names>P</given-names></name><name><surname>Carmody</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods</article-title>. <source>J Med Microbiol</source> <year>2009</year>;<volume>58</volume>(<supplement>Pt 5</supplement>):<fpage>683</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr9-0956462412472792"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Unemo</surname><given-names>M</given-names></name><name><surname>Golparian</surname><given-names>D</given-names></name><name><surname>Hestner</surname><given-names>A</given-names></name></person-group>. <article-title>Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010</article-title>. <source>Euro Surveill</source> <year>2011</year>;<volume>16</volume>:<fpage>1</fpage>–<lpage>3</lpage>. <comment>See <uri xlink:href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19792">http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19792</uri></comment> (<access-date>last checked 29 August 2012</access-date>)</citation></ref>
<ref id="bibr10-0956462412472792"><label>10</label><citation citation-type="web"><collab>Sexually Transmitted Disease Services</collab>. <comment><italic>Sentinel Surveillance of Sexually Transmitted Diseases (STDs) in South Australia.</italic> Report 2. 2010</comment>. <year>2011</year>. <comment>See <uri xlink:href="http://www.stdservices.on.net/publications/">http://www.stdservices.on.net/publications/</uri></comment> (<access-date>last checked 29 August 2012</access-date>)</citation></ref>
<ref id="bibr11-0956462412472792"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>G</given-names></name></person-group>. <article-title>Computerization of clinic records: the resource utilization system for a sexually transmitted diseases clinic</article-title>. <source>Sex Transm Dis</source> <year>1989</year>;<volume>16</volume>:<fpage>1</fpage>–<lpage>6</lpage></citation></ref></ref-list>
</back>
</article>